Search 

BioProduction by Sekisui offers contract development and manufacturing services for the biopharmaceutical industry.  Our facility in the UK has over 40 years of large scale microbial fermentation and purification experience and are in the midst of a $19M GMP expansion. 

We offer expertise in bioprocess development, scale up and manufacturing of enzymes, plasmids, chromatography ligands and other proteins for use in biopharmaceuticals.

CDMO with expertise in manufacturing enzymes, antibody fragments, plasmids and other proteins produced through microbial fermentation.  We are currently expanding our cGMP capabilities to take on additional projects.

Silence Therapeutics is a leading RNAi company, developing highly innovative medicines with life-saving potential for patients with serious and rare diseases, based upon its proprietary mRNAi GOLD platform.


RNAi enables the targeting of virtually any disease related protein including those classed as undruggable by traditional therapeutic approaches. Our proprietary mRNAi GOLD platform enables highly specific gene silencing of any gene expressed in liver hepatocytes, opening up the potential to treat many diseases - from rare hematological disorders to widespread cardiovascular diseases. The validated and modular nature of this approach means we can move very rapidly from target identification through to IND/CTA enabling studies. Products developed using our technology are patient friendly with subcutaneous administration and infrequent dosing.

The Company is in a strong position to maximize the potential of its IP and technology through collaborations and the advancement of internal programs toward the clinic.

Pioneering medicines for crossing biological barriers. SomaServe operate the PolyNaut platform: technologies for targeted and cell specific delivery of gene therapies and protein therapeutics to the brain and other intractable regions.

Therakind, a private European pharmaceutical company, is focused on creating and developing safe, effective, authorised paediatric and speciality niche medicines. Our primary objective is to increase the availability of authorised paediatric and niche medicines and to ensure that the medication used today is both safe and effective.



Therakind's team has extensive experience in the paediatric pharmaceutical sector, we have the expertise to design clinical programmes and regulatory strategy to advance medicines from concept through to regulatory approval.



Therakind was pivotal in the process of bringing Buccolam®, a treatment for prolonged acute convulsive seizures, to the EU market. This product has been sold to Viropharma Inc (now Shire Pharmaceuticals) and is marketed across Europe.



Therakind is a private European pharmaceutical company established in 2006.

Established in 1989, the BIA (BioIndustry Association) exists to encourage and promote a financially sound and thriving bioscience sector within the UK economy and concentrates its efforts on emerging enterprise and the related interests of companies Founded over 20 years ago at the infancy of biotechnology, the BIA is the trade association for innovative enterprises involved in UK bioscience. Members include emerging and more established bioscience companies; pharmaceutical companies; academic, research and philanthropic organisations; and service providers to the bioscience sector. The BIA represents the interests of its members to a broad section of stakeholders, from government and regulators to patient groups and the media. Our goal is to secure the UK's position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people's lives.

Vaccitech is a clinical stage T cell immunotherapy company developing products to treat and prevent cancer and infectious diseases. The company’s proprietary technology platform, comprising
Chimpanzee Adenovirus (prime) and MVA (boost) is exceptional at inducing, boosting and maintaining CD8+ and CD4+ T cells, as well as antibodies. The Vaccitech prime-boost platform is licensed from one of the most prestigious vaccine research institutes in the world, the Jenner Institute at the University of Oxford. Vaccitech currently has a Phase 2 clinical program for prostate cancer, a Phase 1 clinical program for chronic HBV and is poised to enter the clinic with HPV and NSCLC therapeutics. The company is also co-developing products for MERS coronavirus and Herpes Zoster with international collaborators and has outlicensed its rights to the ChAdOx COVID-19 vaccine being developed by the University of Oxford to AstraZeneca. Vaccitech is backed by leading institutions including M&G, GV, Gilead Sciences, Sequoia Capital China, Korea Investment Partners and Oxford Sciences Innovation.